Research Progress of Multidrug Resistance of Breast Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

ZHAO Fei , JIANG Jun

Breast Disease Center, Southwest Hospital,The Third Military Medical University, Chongqing 400038, China;

Corresponding author：

Keywords：

Breast neoplasm; Chemotherapy; Multidrug resistance

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To review the recent studies on the multidrug resistance of breast cancer.
Methods The literatures of recent years on the studies of multidrug resistance, multidrug resistance protein and breast cancer resistance protein were reviewed.
Results Multidrug resistance resulted from multiple factors. How to identify the sensibility of chemotherapy drugs and select individual therapeutic regime early were important to improve the survival rate and life quality of breast cancer patients.
Conclusion These studies on multidrug resistance of breast cancer are helpful to predicting the effect and outcome of chemotherapy and overcoming the barrier of drug resistance.

Citation： ZHAO Fei,JIANG Jun. Research Progress of Multidrug Resistance of Breast Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2004, 11(1): 36-39. doi: Copy

1.	Arnal M, Franco N, Fargeot P, et al. Enhancement of mdr1 gene expression in normal tissue adjacent to advanced breast cancer [J].Breast Cancer Res Treat, 2000; 61(1)∶13.
2.	Schneider J, GonzalezRoces S, Pollan M, et al. Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue m astectomy after induction chemotherapy [J]. Breast Cancer Res, 2001; 3(3)∶183.
3.	Ratnasinghe D, Daschner PJ, Anver MR, et al. Cyclooxygenase2, Pglycoprotein170 and drug resistance; is chemoprevention against multidrug resistance possible?[J]. Anticancer Res, 2001; 21(3C)∶2141.
4.	Beck J, Bohnet B, Brugger D, et al. Multiple gene expression analysis reveals distinct differences between G2 and G3 stage breast cancers, and correlations of PKC eta with MDR1, MRP and LRP gene expression [J].Br J Cancer, 1998; 77(1)∶87.
5.	Lucci A, Cho WI, Han TY, et al. Glucosylceramide: a marker for multipledrug resistant cancers [J]. Anticancer Res, 1998; 18(1B)∶475.
6.	Liu YY, Han TY, Giuliano AE, et al. Ceramide glycosylation potentiates cellular multidrug resistance [J]. FASEB J, 2001; 15(3)∶719.
7.	Chandrasekharan NV, Dai H, Roos KL, et al. COX3, a cyclooxygenase1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression [J]. Proc Natl Acad Sci USA, 2002; 99(21)∶13926.
8.	Janz M, Harbeck N, Dettmar P, et al. Ybox factor YB1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI1 [J]. Int J Cancer, 2002; 97(3)∶278.
9.	Jedlitschky G, Burchell B, Keppler D. The multidrug resistance protein 5 functions as an ATPdependent export pump for cyclic nucleotides [J]. J Biol Chem, 2000; 275(39)∶30069.
10.	Kanzaki A, Toi M, Nakayama K, et al. Expression of multidrug resistancerelated transporters in human breast carcinoma [J]. Jpn J Cancer Res, 2001; 92(4)∶452.
11.	Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF7 breast cancer cells [J]. Proc Natl Acad Sci USA, 1998; 95(26)∶15665.
12.	Maliepaard M, Scheffer GL, Faneyte IF, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues [J]. Cancer Res, 2001; 61(8)∶3458.
13.	Litman T, Brangi M, Hudson E, et al. The multidrugresistant phenotype associated with overexpression of the new ABC halftransporter, MXR (ABCG2) [J]. J Cell Sci, 2000; 113(Pt 11)∶2011.
14.	Faneyte IF, Kristel PM, Maliepaard M, et al. Expression of the breast cancer resistance protein in breast cancer [J]. Clin Cancer Res, 2002; 8(4)∶1068.
15.	Perquin M, Oster T, Maul A, et al. The glutathionerelated detoxification pathway in the human breast: a highly coordinated system disrupted in the tumour tissues [J]. Cancer Lett, 2000; 158(1)∶7.
16.	Jarvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase Ⅱ alpha associate with ErbB2 amplification and affect sensitivity to topoisomerase Ⅱ inhibitor doxorubicin in breast cancer [J]. Am J Pathol, 2000; 156(3)∶839.
17.	Coon JS, Marcus E, GuptaBurt S, et al. Amplification and overexpression of topoisomerase Ⅱ alpha predict response to anthracyclinebased therapy in locally advanced breast cancer [J]. Clin Cancer Res, 2002; 8(4)∶1061.
18.	Fedier A, Schwarz VA, Walt H, et al. Resistance to topoisomerase poisons due to loss of DNA mismatch repair [J]. Int J Cancer, 2001; 93(4)∶571.
19.	Matsumoto Y, Takano H, Kunishio K, et al. Hypophosphorylation of topoisomerase Ⅱ alpha in etoposide (VP16)resistant human carcinoma cell lines associated with carboxyterminal truncation [J]. Jpn J Cancer Res, 2001; 92(7)∶799.

1. Arnal M, Franco N, Fargeot P, et al. Enhancement of mdr1 gene expression in normal tissue adjacent to advanced breast cancer [J].Breast Cancer Res Treat, 2000; 61(1)∶13.
2. Schneider J, GonzalezRoces S, Pollan M, et al. Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue m astectomy after induction chemotherapy [J]. Breast Cancer Res, 2001; 3(3)∶183.
3. Ratnasinghe D, Daschner PJ, Anver MR, et al. Cyclooxygenase2, Pglycoprotein170 and drug resistance; is chemoprevention against multidrug resistance possible?[J]. Anticancer Res, 2001; 21(3C)∶2141.
4. Beck J, Bohnet B, Brugger D, et al. Multiple gene expression analysis reveals distinct differences between G2 and G3 stage breast cancers, and correlations of PKC eta with MDR1, MRP and LRP gene expression [J].Br J Cancer, 1998; 77(1)∶87.
5. Lucci A, Cho WI, Han TY, et al. Glucosylceramide: a marker for multipledrug resistant cancers [J]. Anticancer Res, 1998; 18(1B)∶475.
6. Liu YY, Han TY, Giuliano AE, et al. Ceramide glycosylation potentiates cellular multidrug resistance [J]. FASEB J, 2001; 15(3)∶719.
7. Chandrasekharan NV, Dai H, Roos KL, et al. COX3, a cyclooxygenase1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression [J]. Proc Natl Acad Sci USA, 2002; 99(21)∶13926.
8. Janz M, Harbeck N, Dettmar P, et al. Ybox factor YB1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI1 [J]. Int J Cancer, 2002; 97(3)∶278.
9. Jedlitschky G, Burchell B, Keppler D. The multidrug resistance protein 5 functions as an ATPdependent export pump for cyclic nucleotides [J]. J Biol Chem, 2000; 275(39)∶30069.
10. Kanzaki A, Toi M, Nakayama K, et al. Expression of multidrug resistancerelated transporters in human breast carcinoma [J]. Jpn J Cancer Res, 2001; 92(4)∶452.
11. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF7 breast cancer cells [J]. Proc Natl Acad Sci USA, 1998; 95(26)∶15665.
12. Maliepaard M, Scheffer GL, Faneyte IF, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues [J]. Cancer Res, 2001; 61(8)∶3458.
13. Litman T, Brangi M, Hudson E, et al. The multidrugresistant phenotype associated with overexpression of the new ABC halftransporter, MXR (ABCG2) [J]. J Cell Sci, 2000; 113(Pt 11)∶2011.
14. Faneyte IF, Kristel PM, Maliepaard M, et al. Expression of the breast cancer resistance protein in breast cancer [J]. Clin Cancer Res, 2002; 8(4)∶1068.
15. Perquin M, Oster T, Maul A, et al. The glutathionerelated detoxification pathway in the human breast: a highly coordinated system disrupted in the tumour tissues [J]. Cancer Lett, 2000; 158(1)∶7.
16. Jarvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase Ⅱ alpha associate with ErbB2 amplification and affect sensitivity to topoisomerase Ⅱ inhibitor doxorubicin in breast cancer [J]. Am J Pathol, 2000; 156(3)∶839.
17. Coon JS, Marcus E, GuptaBurt S, et al. Amplification and overexpression of topoisomerase Ⅱ alpha predict response to anthracyclinebased therapy in locally advanced breast cancer [J]. Clin Cancer Res, 2002; 8(4)∶1061.
18. Fedier A, Schwarz VA, Walt H, et al. Resistance to topoisomerase poisons due to loss of DNA mismatch repair [J]. Int J Cancer, 2001; 93(4)∶571.
19. Matsumoto Y, Takano H, Kunishio K, et al. Hypophosphorylation of topoisomerase Ⅱ alpha in etoposide (VP16)resistant human carcinoma cell lines associated with carboxyterminal truncation [J]. Jpn J Cancer Res, 2001; 92(7)∶799.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Research Progress of Multidrug Resistance of Breast Cancer

Abstract Full text Figures/Tables Video References Cited by

Format

Content